Orexigen® Therapeutics to Speak at UBS Global Life Sciences Conference

SAN DIEGO, Sept. 16 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the UBS Global Life Sciences Conference.  The details are as follows:

Date:  September 21, 2010

Time:  7:30am (EDT)

Location: Grand Hyatt New York

Speaker: Michael Narachi, Chief Executive Officer



A live webcast of the presentation can be accessed in the investor relations section of the Orexigen website at http://www.orexigen.com, and will be available for 14 days following the presentation. Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.